Kimia Farma Tbk PT
IDX:KAEF

Watchlist Manager
Kimia Farma Tbk PT Logo
Kimia Farma Tbk PT
IDX:KAEF
Watchlist
Price: 600 IDR
Market Cap: 3.3T IDR
Have any thoughts about
Kimia Farma Tbk PT?
Write Note

Net Margin
Kimia Farma Tbk PT

-17.1%
Current
-5%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-17.1%
=
Net Income
-1.7T
/
Revenue
10.1T

Net Margin Across Competitors

Country ID
Market Cap 3.3T IDR
Net Margin
-17%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 755.8B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 2.7T DKK
Net Margin
35%
Country US
Market Cap 351.1B USD
Net Margin
17%
Country US
Market Cap 251.8B USD
Net Margin
19%
Country CH
Market Cap 200.1B CHF
Net Margin
20%
Country UK
Market Cap 161.8B GBP
Net Margin
13%
Country CH
Market Cap 171.5B CHF
Net Margin
35%
Country US
Market Cap 151.5B USD
Net Margin
7%
No Stocks Found

Kimia Farma Tbk PT
Glance View

Market Cap
3.3T IDR
Industry
Pharmaceuticals

PT Kimia Farma Tbk engages in the production and distribution of healthcare products. The company is headquartered in Jakarta, Dki Jakarta and currently employs 11,668 full-time employees. The company went IPO on 2001-07-04. The firm produces medical devices and chemical materials. The firm is also involved in producing vegetable oil, iodine, and salts. Its products include Glucokaf, Diazink, Oracef, Kifarox, Magacid Suspension, Magaside Chewable Tablets, Nitrocafe Retarded, Nitrocafe Retard Forte, Trinolon, Raistine, VAGIZOL, Neviral, Hiviral Tablet, Duviral, Codipront Cum Expectorant, RETHAPHYL SR, and SUPRAFLU. Its generic products include PETHIDIN Hcl, PARACETAMOL, Diclofenac Sodium, MEPHANAMIC ACID, ANTALGIN, ANTASIDE DOEN, PYRANTEL, ALBENDAZOLE, METRONIDAZOLE TABLET, NEO BLOOD ADDING TABLET, FERROUS SULOATE SYRUP, DIMENHYDRINATE, ACYCLOVIR, AMBROXOL HCL, CHLOROQUINE, CHLORPROMAZINE HCL, CODEIN, CLOPIDOGREL, ERGOTAMINE COFFEE, METHYLERGOMETRINE TABLET SALUTE, MELOXICAM, and Pherphenazine.

KAEF Intrinsic Value
1 038.26 IDR
Undervaluation 42%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-17.1%
=
Net Income
-1.7T
/
Revenue
10.1T
What is the Net Margin of Kimia Farma Tbk PT?

Based on Kimia Farma Tbk PT's most recent financial statements, the company has Net Margin of -17.1%.